Building Vaccine Manufacturing Capacity in Emerging Markets

Rwanda’s Rise as a Vaccine Research and Manufacturing Hub

Rwanda is steadily establishing itself as a key player in vaccine research and manufacturing across Africa. The country is investing in the necessary expertise, infrastructure, and regulatory systems to produce vaccines locally, aiming to meet international standards. This effort has drawn attention from global health organizations, including the International Vaccine Institute (IVI), which has been actively involved in supporting Rwanda’s initiatives.

Dr. Jerome Kim, Director General of IVI, shared insights on Rwanda’s progress, challenges in vaccine development for low- and middle-income countries, and how the nation is preparing to meet global production and regulatory benchmarks. His perspectives highlight the importance of collaboration between governments, academic institutions, and international organizations in advancing public health.

Understanding IVI’s Mission and Role in Global Health

IVI is an international organization dedicated to developing vaccines for global health. Its mission includes discovering, developing, and delivering safe, effective, and affordable vaccines, with a focus on vaccine equity and security. Dr. Kim emphasized that IVI fills a critical gap by supporting innovations for diseases affecting poorer countries, where large pharmaceutical companies may not see sufficient financial returns.

He also explained that IVI brings together diverse perspectives—from finance and the pharmaceutical industry to global health—to ensure that vaccines are developed and delivered effectively. This approach helps address the needs of populations that are often overlooked by commercial interests.

The Joint Symposium with the University of Rwanda

A recent joint symposium between IVI and the University of Rwanda was part of broader discussions aimed at advancing health through research and innovation. The event provided a platform for sharing knowledge and strengthening partnerships between IVI and local institutions. It also highlighted the role of academic collaboration in building capacity for vaccine development.

The IVI Board of Trustees includes representatives from various countries, including Rwanda, and features experts in global health, finance, and the pharmaceutical industry. These members play a crucial role in guiding IVI’s strategic direction and ensuring that its work aligns with global health priorities.

Building Local Expertise and Capacity in Rwanda

IVI’s regional office in Rwanda is focused on strengthening local vaccine expertise and supporting industry growth. This involves training scientists, researchers, and professionals who will eventually lead vaccine research, clinical trials, and manufacturing efforts.

Dr. Kim noted that while building a vaccine factory is relatively straightforward, the real challenge lies in training the human resources needed to operate it. Rwanda has recognized this and is taking steps to develop the necessary skills and knowledge.

The symposium also covered the process of moving a vaccine from laboratory concepts to regulatory approval and WHO prequalification. This is essential for ensuring that vaccines can be procured by UN agencies like UNICEF.

Progress in African Vaccine Manufacturing

Recent developments in Africa show promising signs of progress. For example, South Africa is testing the first oral cholera vaccine manufactured on the continent, produced by BioVac using technology transferred from IVI. If successful, this would mark a significant milestone in vaccine manufacturing on the continent.

Board members visiting Rwanda were impressed by the country’s advanced digital health systems, including real-time vaccination data, disease alerts, ambulance routing, and drone deliveries. These capabilities have boosted confidence in Rwanda’s ability to support vaccine development and manufacturing.

Lessons from Korea and the Path Forward for Rwanda

Dr. Kim used Korea as an example of how IVI has helped a country build its vaccine manufacturing capacity. In the 1990s, Korea had limited biotech capabilities, but through IVI’s support, it has become a major player in vaccine production.

For Rwanda, the approach is similar but tailored to the country’s unique needs. IVI did not seek direct funding but instead focused on forming partnerships to attract external resources and build scientific and regulatory capabilities.

One notable initiative is Achieve Africa, a $100 million project for African-led HIV vaccine research. This initiative highlights the growing role of African leadership in shaping global health strategies.

Steps Toward Self-Sufficiency in Vaccine Production

Rwanda is taking several steps to build the expertise, facilities, and regulatory capacity needed for local vaccine development. This includes creating high-quality animal testing facilities, small-scale manufacturing sites that meet international standards, and trained clinical trial teams.

Regulatory frameworks must also evolve to understand novel vaccine platforms, and funding mechanisms need to support products through each phase of development. Additionally, Rwanda must be prepared to generate the data required by regulatory bodies like WHO’s SAGE.

Training and Capacity Building Initiatives

Human capacity remains one of the biggest needs in vaccine development. However, Rwanda is already making progress through training programs. IVI hosts the WHO Global Training Hub for Biomanufacturing, which has trained over 1,000 people globally. Graduates then continue their training at the mRNA hub in South Africa, learning from an operational mRNA manufacturing facility.